Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_assertion type Assertion NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_head.
- NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_assertion wasGeneratedBy ECO_0000203 NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_provenance.
- NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_assertion wasDerivedFrom befree-20140225 NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_provenance.
- NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_assertion SIO_000772 15988530 NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_provenance.
- NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_assertion evidence source_evidence_literature NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_provenance.
- NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_assertion description "[The clinical success of the ABL tyrosine kinase inhibitor imatinib in chronic myeloid leukaemia (CML) serves as a model for molecularly targeted therapy of cancer, but at least two critical questions remain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP580896.RAJzhdpS0l-95M3TONOI-opJad5m3Lx_facS4qtiQtP3A130_provenance.